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Background: Elevated high-sensitivity C-reactive protein (hsCRP) increases the risk of cardiovascular disease (CVD) in
the general population, but its role as a predictive marker in HIV-positive patients remains unclear. Aim of the study
was to evaluate whether hsCRP or other biomarkers are independent predictors of CVD risk in HIV-infected patients.
Methods: Retrospective, nested case–control study. HIV-positive men and women (35–69 years of age) receiving
combination antiretroviral therapy (cART) were included. Cases (n = 35) had a major CVD event. Controls (n = 74)
free from CVD events for at least 5 years from starting ART were matched on diabetes and smoking. HsCRP, D-dimer,
P-selectin, interleukin-6 (IL-6), tissue plasminogen activator, plasminogen activator inhibitor-1 levels were measured.
Results: High hsCRP was associated with CVD risk, independently of traditional cardiovascular risk factors, HIV
replication and the type of ART received at the time of sampling (adjusted odds ratio 8.00 [1.23-51.94] comparing
>3.3 mg/L with <0.9 mg/L; P = 0.03). Higher IL-6 and P-selectin levels were also independently associated with
increased CVD risk, although the association was weaker than for hsCRP. Higher total cholesterol and lower HDL
cholesterol increased CVD risk, independent of hsCRP.
Conclusion: hsCRP may be a useful additional biomarker to predict CVD risk in HIV-infected patients receiving cART.
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Combination antiretroviral therapy (cART) has substan-
tially reduced HIV-related morbidity and mortality [1]. As a
result, HIV-infected people have longer life-expectancy and
the focus of therapy has shifted to long-term management
of the infection, particularly treatment-related side-effects
and comorbidities. Cardiovascular disease (CVD) has
received particular attention, as it is associated with
considerable morbidity and mortality [2], and there is* Correspondence: deluca.andrea@fastwebnet.it
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reproduction in any medium, provided the orcumulating data showing that HIV-infected patients
are at higher risk of CVD than uninfected controls [3,4].
However, controversy exists over the relative contribution
of host factors (e.g. smoking, hypertension, diabetes, male
sex and older age), rather than the virus itself or use of
cART to this increased risk. For HIV infection and cART,
this effect may occur via their modification of traditional
risk factors [5], as well as pathogenic pathways leading to
atherosclerosis and CVD (e.g. inflammation and endothelial
dysfunction) [3,6-10].
Although several studies have suggested a positive associ-
ation between cART and CVD risk [3,11,12], there is also
evidence that cART may improve endothelial function and
protect against atherosclerosis [13,14]. Furthermore, differ-
ences exist in the relative risk of CVD between, and within,l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Collection on Adverse Events of Anti-HIV Drugs (D:A:D)
Study Group found an association between the use of
specific protease inhibitors, of abacavir and of didanosine
and an increased risk of myocardial infarction [22], but not
all subsequent studies have confirmed this result [23].
Research into CVD risk factors in the general population
has identified a number of predictive biomarkers, such as
apolipoprotein B, total cholesterol, interleukin-6 (IL-6),
serum amyloid A, D-dimer, tissue plasminogen activator
(t-PA), plasminogen activator inhibitor-1 (PAI-1), P-selectin,
intercellular adhesion molecule 1 (ICAM-1), vascular
adhesion molecule 1 (VCAM-1) and, most importantly,
C-reactive protein (CRP) as determined by high sensitivity
techniques (hsCRP) [24-29]. HsCRP levels <1.0 mg/L,
1.0–3.0 mg/L and >3.0 mg/L indicate low, average and
high CVD risk, respectively [30].
Given the increased risk of CVD in HIV-infected
patients, the predictive role of such biomarkers in this
patient population is of interest. Several potential CVD
markers have been investigated in HIV-positive patients,
including lipoprotein particles, measurements of carotid
artery intima–media thickness and of arterial stiffness,
tumor necrosis factor-α, IL-6, IL-10, myeloperoxidase,
platelet (P)-selectin, leptin, D-dimer, adiponectin, soluble
VCAM-1, ICAM-1 and ICAM-3, and hsCRP [31-33]. A
recent analysis on the SMART study found an association
between CRP, IL-6 and d-dimer and the risk of CVD
events [34].
Our primary objective was to evaluate whether hsCRP
predicts CVD risk in HIV-infected patients, independently
of other established risk factors, using the data of persons
enrolled in two Italian cohorts. Our secondary objective




We studied patients enrolled in two cohort studies; the
Icona Foundation Cohort and the Catholic University of
the Sacred Heart (CUSH) clinical database, Rome. In
CUSH, data have been collected as part of routine clinical
care since 1997 (full details are reported elsewhere [35]).
The Icona Foundation Study includes HIV-positive patients
presenting at 67 infectious disease centers across Italy and
represents the continuation of the Italian Cohort of
Antiretroviral-Naïve Patients (I.Co.N.A) study, which has
previously been described [36]. After enrolment, follow-up
clinical visits occur approximately every 6 months in the
Icona Foundation Study and every 3 months in CUSH.
All patients provided written consent to participate in
Icona Foundation Study and in CUSH, following procedures
in accordance with the ethical standards of the responsible
committee on human experimentation and the HelsinkiDeclaration. In both studies, patients informed consent
includes a specification for use of samples for further
research in HIV. No specific consent for inclusion in
the current analysis was therefore needed. The studies
and the corresponding informed consents were approved by
the Ethics Committees of the various ICONA clinical sites
(see Appendix) and that of the Catholic University for
CUSH. Inclusion criteria for this analysis were age
35–69 years and no history of a major CVD event before
starting cART and no evidence of any other inflammatory
disorder over the 3 months prior to the date of the stored
plasma sample. Exclusion criteria were current use of
active hormonal-based therapy and of therapy with
anti-inflammatory drugs or statins. A small proportion of
patients had used these drugs prior to the date of the
stored sanple.
Analysis design
We conducted a retrospective, matched case–control
study nested within CUSH and the Icona Foundation
Study involving HIV-infected patients with CVD (cases)
or without CVD (controls). CVD cases were defined as
HIV-infected patients who had a major cardiovascular
event (acute myocardial infarction; stable or unstable
angina or were undergoing myocardial revascularization
procedures) while receiving cART (a regimen including
at least 3 antiretrovirals), and for whom at least one
plasma sample was stored before the CVD event.
Within each cohort, HIV-infected controls (a mini-
mum of two per each case) were defined as patients
who were currently free of CVD events (i.e. had never
developed CVD events), had at least 5 years of follow-up
after cART initiation and had at least one plasma sample
stored over the observation period.
Cases and controls were matched on previous history
of diabetes and smoking status. The ‘index time’ for analysis
was fixed at the date of the CVD event for cases and at last
follow-up for controlsBecause date of sample for controls
was on average much more recent than that of cases,
calendar year and time between the date of sample
and the index time were included as an additional
adjusting factor in the multivariable analyses.
Sample collection
In CUSH, plasma samples are collected each time a viral
load assay is performed (i.e. approximately every 3 months),
and stored at −80°C. In the Icona Foundation Study, plasma
samples are stored at the time of enrolment and at least
once a year. In both cohorts, plasma samples are collected
using Vacutainer® collection tubes (lavender top, containing
ethylenediaminetetraacetic acid, Becton Dickinson, New
Jersey, USA). In the case of ICONA foundation Study,
samples are initially kept frozen at the various clinical
sites at −20°C or −80°C and subsequently shipped using
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are kept at −80°C until use for retrospective analysis. Dates
of sampling were (ranges) 1999–2008 for cases and
2006–2008 for controls for CUSH, and 1998–2004 for
cases and 2000–2004 for controls for the Icona Foundation
Study. As a general rule, the most recent plasma sample
stored before the analysis index time was analyzed in both
cases and matching pair of controls (late samples). How-
ever, for some cases and controls, if more than one stored
sample was available, biomarkers were measured using
an additional earlier sample (early samples). To avoid
bias, laboratory personnel was blind to whether the
sample was coming from a case or a control. Samples,
which were labelled with a unique identifier so that they
could be linked with patients ID and their clinical data for
statistical analysis, were analyzed in random order.Biochemical analyses
Total cholesterol and HDL were measured using
standard techniques by local laboratories, while bio-
markers were analyzed by the Laboratory of Genetic
and Environmental Epidemiology, Catholic University of
Campobasso, Italy. hsCRP was measured by nephelometry
using an automatic analyzer (ILab 350, Instrumentation
Laboratory, Milan, Italy). Quality control was performed
using an internal laboratory standard; the inter-day coeffi-
cient of variation (CV) was 2%. D-Dimer was evaluated
utilizing a latex particle-enhanced immunoturbidimetric
assay (IL ACL9000, Instrumentation Laboratory, Milan,
Italy). Quality control was performed using an in-house
citrate plasma pool; inter-and intra-day CV was 7.6%
and 5.4%, respectively. P-selectin (Bender MedSystems
Europe, Vienna, Austria), IL-6 (R&D System Europe,
Abingdon, UK), t-PA and PAI-1 (American Diagnostica
Inc. GmbH, Pfungstadt, Germany) were measured utilizing
commercially available enzyme-linked immunosorbent
assay (ELISA) kits, as specified by the manufacturers. The
intra-assay CV, using in-house citrate plasma, were,
according to the manufacturer, 4.3%, 10.5%, 4.8% and 9.8%
respectively.
The detection limit of the different assays were
1.06 ng/ml for P-selectin, 1.0 ng/ml for t-PA, 1.0 ng/ml
for PAI-1 and 0.70 pg/ml for IL-6.Sample size calculation and statistical analysis
By setting the type I error α at 5%, and assuming that
40% of patients had a hsCRP level above 3 mg/L [30]
and two controls per case, we calculated that 35 cases
and 70 controls were necessary to achieve 80% power to
detect an OR for CVD risk of 3.3 for a hsCRP level
above the pre-defined threshold (vs. below 1 mg/L).
Smaller effects were expected for the other biomarkers
which the study was not powered on.Summary statistics and illustrations appropriate for
matched case–control studies were used to summarize
key findings [37]. Conditional logistic regression analysis
for matched case–control studies was performed to
evaluate the association between the baseline characteris-
tics of the patients as well as the levels of each biomarker
with the risk of CVD events. Separate analyses were
performed using the late samples as well as using all sam-
ples combinedby tertiles of each biomarker (for the early
samples, sparse data led to numerical problems in the
multivariable analysis, resulting in an unstable model);
cut-offs for the tertiles were chosen using the distribution
of the measures in the combined dataset. For hsCRP,
sensitivity analyses were also performed using the categor-
ies of <1, 1–3 and >3 mg/L as these had been clinically
validated in the general population.
Models with log2 transformed biomarker levels were
also used, estimating the increased risk of CVD associated
with a one log2 difference in biomarker levels. Separate
models were fit for each biomarker and, because of the
large number of parameters involved, we decided a priori
not to fit the model mutually controlling for all biomarkers.
The following covariates assessed at the date of stored sam-
ples were considered for the adjusted analyses: calendar
year, duration of time between the date of sample and the
analysis time, age, total cholesterol, HDL, CD4+ cell count
and viral load, cumulative exposure to nonnucleoside re-
verse transcriptase inhibitors (NNRTIs), nucleoside reverse
transcriptase inhibitor (NRTIs) and protease inhibitor (PIs)
prior to sample, and co-infection with hepatitis B or C.
[38]. Sensitivity analyses, were performed on the combined
samples set additionally controlling for one of these factors
at the time: body mass index (BMI), estimated glomerular
filtration rate (eGFR, by the MDRD formula) and prior
use of statins. In the analysis using the combined data set,
standard errors were adjusted for non-independence
between biomarkers coming from the same individual
using the cluster option for clogit in STATA [39]. All statis-
tical analyses were performed using SAS version 9.1, Cary,
North Carolina, United States and STATA software
(StataCorp. 2008. Stata Statistical Software: Version 10.1,
College Station, Texas, USA). All tests were two-sided and
assumed a level of significance of 0.05.
Results
Baseline characteristics
We studied 109 patients (35 cases, 74 controls) of whom 17
cases, 40 controls were from CUSH and 18 cases, 34 con-
trols from the Icona Foundation Study. The distribution of
the matching variables in cases and controls was: smokers/
diabetics (3;4), non-smokers/diabetics (4;8), smokers/non-
diabetics (22;50), non-smokers/non-diabetics (6;12).
Characteristics of cases and controls at the time of the
late samples are summarized in Table 1. Compared with
Table 1 Main characteristics of cases and matched controls at time of late sample
Characteristic Cases Controls p-value#
(n= 33)* (n= 71)*
Age, years
median (IQR) 47 (42, 53) 45 (39, 49) 0.139
Gender, n(%)
Female 1 (3%) 8 (11%) 0.205
Mode of HIV trasmission, n (%)
IDU 13 (39%) 21 (30%)
Homosexual contacts 7 (21%) 18 (25%) 0.365
Heterosexual contacts 12 (36%) 24 (34%) 0.657
Other/Unknown 1 (3%) 8 (11%) 0.143
Co-infection with HBV or HCV, n (%)
Yes 16 (48%) 26 (37%) 0.224
CD4 count, cells/mm3
Median (IQR) 550 (451, 730) 525 (370, 768) 0.805
HIV RNA, log10 copies/mL
Median (IQR) 2.1 (1.7, 4.0) 1.7 (1.7, 2.7) 0.164
Median total cholesterol (IQR) 0.006
nmol/L 5.4 (4.6, 6.3) 4.9 (4.0, 5.6)
mg/dL 209.0 (180.0, 247.0) 192.0 (155.0, 217.0)
Median HDL-cholesterol (IQR) 0.130
nmol/L 2.1 (1.8, 2.3) 2.3 (1.9, 2.6)
mg/dL 40.0 (35.0, 45.0) 44.0 (37.0, 51.0)
cART-treated before late sample, n (%) 0.115
Yes 29 (88%) 54 (76%)
AIDS diagnosis, n (%) 0.586
Yes 6 (18%) 16 (23%)
Cumulative exposure to NRTI, months 0.003
Median (IQR) 51 (27, 102) 121 (40, 145)
Cumulative exposure to NNRTI, months 0.021
Median (IQR) 3 (0, 27) 30 (0, 77)
Cumulative exposure to PI, months 0.020
Median (IQR) 26 (8, 38) 52 (11, 89)
Calendar year of sample <.001
Median (IQR) 2003 (2001, 2006) 2008 (2003, 2008)
Median duration between late sample and analysis time, months 3 (2, 12) 8 (7, 28) 0.051
Prior use of statins°, n (%) 0.263
Yes 5 (15%) 4 (6%)
Body Mass Index§, kg/m2 0.366
Median (IQR) 23.7 (21.7, 25.8) 23.1 (21.3, 26.3)
eGFR^ (MDRD formula), ml/min/1.73 m2 0.637
Median (IQR) 92 (80, 116) 86 (77, 98)
*2 cases and 4 controls had no late sample available.
#from fitting a conditional logistic regression model (continuous variables in log scale).
°Current use (i.e. use during the 3 months before sample) was an exclusion criterion.
§ available in 21 cases and 58 controls.
^ available in 24 cases and 56 controls.
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cumulative exposure to ART, regardless of drug class and
alate sample that was stored less recently, but closer
to the analysis time (Table 1). The index pathology
for the 35 cases was: acute myocardial infarction
(n=30), revascularization procedures (n=1), stable or
unstable angina (n=4).
Biomarkers and risk of CVD
The 35 cases contributed 68 samples (35 early and 33 late
samples) while the 74 controls contributed 145 samples
(74 early and 71 late samples) for biomarkers analysis. In
the unadjusted analysis comparing median values of bio-
markers between cases and controls, the only biomarker
consistently showing a higher median value in cases com-
pared with controls was hsCRP, both in the analysis using
the early samples (2.99 [IQR 1.13-5.99] mg/L in cases ver-
sus 1.62 [0.44-3.50] mg/L in controls, P = 0.09) and late
samples (see Figure 1, P = 0.002). Higher median values
were observed for t-PA in early samples (13.6 [11.1-17.0]
ng/mL in cases versus 8.9 [6.3-13.2] ng/mL in controls,
p<0.001) and P-selectin in late samples (Figure 1) in cases
as compared to controls.
For hsCRP, in early samples, 6/35 (17% of cases) had
levels in the lowest tertile compared with 26/74 (35% of
controls). In contrast, the corresponding percentages
with levels of hsCRP falling in the highest tertile were
14/35 (40%) and 26/74 (26%) for cases and controls, re-
spectively. Similarly, for the late samples alone, 5/33
(15%) of cases and 23/71 (32%) of controls had hsCRP
values in the lowest tertile vs. 14/33 (42%) and 14/71
(18%) in the highest tertile. For the combined data set,









Figure 1 Plasma levels of biomarkers on late samples in cases and m
diamonds in controls), bars indicate interquartile ranges. hsCRP = high-sen
in ng/mL; D-dimer in μg/100 mL; PAI-1 = plasminogen activator inhibitor-1
selectin in μg/100 mL. *p=0.002; #p=0.005 from fitting a conditional logisti49/145 (34%) for controls with hsCRP levels in the low-
est tertile vs. 28/68 (41%) and 33/145 (23%) in the
highest tertile.
Based on univariable and multivariable analyses, on late
samples (Table 2) and the combined dataset (Table 3) a
significantly increased risk of CVD events was observed
for higher values of hsCRP, IL-6 and P-selectin, analyzed
as categorical variables (Tables 2a and 2a), although a
consistent association using the different sets of data was
observed only for hsCRP and, less so, for P-selectin.
Multivariable estimates were adjusted for all factors shown
in the footnote of Tables 2 and 3. Similar results were
obtained by analyzing biomarkers as log-transformed
continuous variables (Tables 2b and 2b), with significant
associations with hsCRP and P-selectin.
None of the other considered biomarkers showed
an independent association with the risk of CVD.
Covariate adjustment showed that the magnitude of
the association was underestimated in the unadjusted
analysis as adjusted OR were even higher, especially
for hsCRP. Use of the combined data set provided
more precise estimates, as a result of increased statistical
power (Tables 3a and b).
Sensitivity analyses using the clinically validated hsCRP
categories [30] showed similar results. In the late samples
data set, adjusted ORs for CVD events were 6.45 (95% CI,
0.64 to 64.42; P = 0.112) for values of 1–3 mg/L and 13.69
(95% CI, 1.35 to 138.9; P = 0.027) for values >3 mg/L, as
compared to values of <1 mg/L. The corresponding values
for the combined data set were 6.5 (95% CI, 1.0 to 41.7;
P = 0.047) and 11.4 (95% CI, 1.8 to 72.3; P = 0.010).
We performed additional sensitivity analyses on the
combined early and late samples dataset. In theD-dimer IL-6 P-selectin#
atched controls. Values indicate medians (full squares in cases and full
sitivity C-reactive protein in mg/L; t-PA = tissue plasminogen activator
in μg/10 mL; IL-6 = interleukin-6 in pg/mL; P-selectin = platelet
c regression (biomarkers in log scale) comparing cases and controls.
Table 2 Univariable and multivariable odds ratios for cardiovascular events according to biomarkers in late samples
Biomarkers Unadjusted OR (95% CI) p-value Adjusted* OR (95% CI) p-value
(a)
Biomarkers as categorical variables
t-PA, ng/ml
<=8.7 (n=27) 1.00 1.00
8.7-14.8 (n=26) 1.56 (0.48, 5.10) 0.459 2.54 (0.52, 12.31) 0.247
>14.8 (n=35) 0.99 (0.31, 3.14) 0.989 0.35 (0.05, 2.31) 0.278
Not measured (n=16) 2.99 (0.81, 10.95) 0.099 4.06 (0.50, 32.74) 0.188
PAI-1, ng/ml
<=112 (n=36) 1.00 1.00
112-207 (n=27) 1.15 (0.33, 3.96) 0.828 0.55 (0.11, 2.74) 0.468
>207 (n=29) 2.99 (0.98, 9.12) 0.054 3.20 (0.75, 13.76) 0.118
Not measured (n=12) 3.62 (0.91, 14.49) 0.069 3.02 (0.23, 39.02) 0.397
D-dimer, ng/ml
<=67 (n=18) 1.00 1.00
67-125 (n=27) 0.55 (0.15, 2.10) 0.384 0.32 (0.06, 1.84) 0.202
>125 (n=28) 0.72 (0.20, 2.61) 0.617 0.63 (0.12, 3.28) 0.585
Not measured (n=31) 1.70 (0.51, 5.62) 0.387 0.55 (0.10, 2.90) 0.482
hsCRP, mg/L
< 0.9 (n=28) 1.00 1.00
0.9-3.3 (n=31) 1.59 (0.46, 5.55) 0.467 5.25 (0.56, 49.67) 0.148
>3.3 (n=28) 4.28 (1.28, 14.36) 0.019 10.71 (1.03, 111.0) 0.047
Not measured (n=17) 2.54 (0.64, 10.11) 0.187 3.88 (0.23, 66.29) 0.349
IL-6, pg/ml
< 0.3 (n=20) 1.00 1.00
0.3-1.9 (n=34) 0.67 (0.20, 2.31) 0.529 0.13 (0.02, 0.86) 0.034
>1.9 (n=37) 1.39 (0.43, 4.46) 0.580 0.36 (0.06, 2.05) 0.249
Not measured (n=13) 2.03 (0.48, 8.50) 0.334 0.64 (0.04, 9.07) 0.738
P-selectin, ng/ml
< 157 (n=38) 1.00 1.00
157-236 (n=28) 1.23 (0.36, 4.19) 0.744 1.40 (0.29, 6.87) 0.676
>236 (n=25) 4.39 (1.43, 13.45) 0.010 3.94 (0.82, 18.88) 0.086
Not measured (n=13) 3.41 (0.88, 13.20) 0.075 2.84 (0.24, 33.51) 0.407
(b)
Biomarkers as continuous variables (Log Scale)
t-PA, ng/ml
Per log2 higher 0.97 (0.55, 1.74) 0.926 0.78 (0.35, 1.76) 0.554
PAI-1, ng/ml
Per log2 higher 1.47 (0.96, 2.24) 0.073 1.40 (0.81, 2.42) 0.233
D-dimer, ng/ml
Per log2 higher 0.89 (0.57, 1.41) 0.626 0.97 (0.55, 1.72) 0.918
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Table 2 Univariable and multivariable odds ratios for cardiovascular events according to biomarkers in late samples
(Continued)
hsCRP, mg/L
Per log2 higher 1.61 (1.18, 2.18) 0.002 1.69 (1.09, 2.64) 0.020
IL-6, pg/ml
Per log2 higher 1.09 (0.81, 1.45) 0.568 1.05 (0.72, 1.53) 0.799
P-selectin, ng/ml
Per log2 higher 2.88 (1.38, 6.02) 0.005 3.14 (1.04, 9.45) 0.042
Estimate performed by a Conditional Logistic Regression Model; CI = confidence interval; HDL = high-density lipoprotein; hsCRP = high-sensitivity C-reactive
protein; IL-6 = interleukin-6; IQR = interquartile range; OR = odds ratio; PAI-1 = plasminogen activator inhibitor-1; t-PA = tissue plasminogen activator.
*Adjusted for duration of time between the date of samples and the analysis time, age, total cholesterol, HDL.
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levels with the risk of CVD events was observed after
further adjusting for BMI (per log2 higher hsCRP, ad-
justed OR 1.45 (1.03, 2.04), p=0.032), for eGFR (per log2
higher hsCRP, adjusted OR 1.38 [95% CI 0.97-1.95],
p=0.071) and for prior use of statins (per log2 higher
hsCRP, adjusted OR 1.31 [95% CI 0.98-1.76], p=0.068).
In the main multivariable model including hsCRP as a
continuous variable (log scale), and using the combined
data set (Table 3b), the following other factors were
independently associated with a greater risk of a CVD
event: a higher total cholesterol (OR, 3.19 per 1 mmol/L
higher [95% CI, 1.57 to 6.46]; P = 0.001), a lower
HDL cholesterol (OR, 0.06 per 0.5 mmol/L higher
[95% CI, 0.01 to 0.31]; P <0.001), a less recent calen-
dar year of the stored sample (OR, 0.92 per 5 years
more recent [95% CI, 0.90 to 0.94]; P <0.001) and
shorter time between the date of sample and the analysis
time (OR, 0.91 per month longer [95% CI, 0.86 to 0.96];
P <0.001).
Discussion and conclusions
From the analysis using the combined set of early and
late samples, we estimated that elevated hsCRP was
associated with increased CVD risk in HIV-positive patients
receiving cART (8-fold risk increase comparing patients
with hsCRP levels >3.3 mg/L with those with <0.9 mg/L). A
key finding was that the effect of hsCRP on CVD risk
appeared to be independent of traditional CVD risk factors
(total cholesterol and low HDL), as well as potential
confounders, such as BMI, renal function and use of statins.
Increased risk of a CVD event was also evident for higher
values of IL-6 and P-selectin, although the association
was weaker than for hsCRP. In addition, higher total choles-
terol and lower HDL cholesterol were confirmed to be
independent predictors of risk of CVD in our HIV-positive
population.
The collection of early and late samples provided
an opportunity to investigate whether the prognostic
value of the studied biomarkers may differ accordingto specific objectives (i.e. to predict the short-term
vs. the long-term risk of CVD). In the unadjusted
analysis, median hsCRP levels were higher in cases
(i.e. with CVD events) than controls (i.e. without
CVD events) for both early and late samples, and
more cases had hsCRP levels in the highest vs. low-
est tertile, although this difference was more signifi-
cant in late samples. Numerical problems due to
sparse data in the analysis including only early
samples, did not allow the calculation of adjusted es-
timates in this subset. Despite this limitation, our
findings suggest that in HIV-infected patients hsCRP may
be a useful marker to predict the medium-to-long term
risk of experiencing CVD events (22 months after the
date of measurement, on average), although the crude
association of this marker with CVD events was actually
stronger for the short term.
Several studies have investigated hsCRP levels in
HIV-positive patients, and the association between
hsCRP and CVD risk. HsCRP levels were not statistically
different between untreated HIV-infected and uninfected
individuals in one study [40], while in another, CRP levels
were higher in HIV-positive patients than the general
population [41]. Approximately 30% of patients with HIV
receiving long-term cART were shown to have CRP
levels >3.0 mg/L [41], the highest CRP levels being
observed in those who were currently treated with
ART [42]. Furthermore, elevated hsCRP levels have
been observed in ART-treated compared with ART-na
ïve HIV-positive patients in another study [43].
In the analysis by Triant et al. including HIV-positive
and -negative patients enrolled in a large US healthcare
system, elevated CRP levels were associated with more
than a four-fold increase in the risk of acute myocardial
infarction compared with HIV-negative patients with
normal CRP [44], but the study used either CRP or
hsCRP tested by different assays, thus not allowing the
analysis of specific thresholds. In a large international
study, the baseline levels of CRP were independently
associated with CVD events, including myocardial
Table 3 Univariable and multivariable OR for CVD risk and biomarkers in early and late samples combined
Biomarkers Unadjusted OR (95% CI) P value Adjusted* OR (95% CI) P value
(a)
Biomarkers as categorical variables
t-PA, ng/ml
<=8.7 (n=61) 1.00 1.00
8.7-14.8 (n=60) 3.87 (1.61, 9.31) 0.003 1.58 (0.33, 7.65) 0.571
>14.8 (n=62) 3.23 (1.35, 7.76) 0.009 0.66 (0.12, 3.75) 0.642
Not measured (n=16) 3.92 (1.42, 10.84) 0.008 0.81 (0.09, 7.07) 0.853
PAI-1, ng/ml
<=112 (n=63) 1.00 1.00
112-207 (n=61) 1.03 (0.45, 2.32) 0.950 1.94 (0.37, 10.33) 0.435
>207 (n=65) 1.87 (0.86, 4.04) 0.113 2.15 (0.48, 9.63) 0.318
Not measured (n=12) 1.70 (0.62, 4.64) 0.300 0.52 (0.04, 7.73) 0.637
D-dimer, ng/ml
<=67 (n=48) 1.00 1.00
67-125 (n=48) 0.71 (0.30, 1.72) 0.451 0.49 (0.10, 2.27) 0.360
>125 (n=49) 0.71 (0.30, 1.72) 0.450 1.03 (0.18, 5.80) 0.972
Not measured (n=31) 1.27 (0.58, 2.76) 0.552 1.01 (0.21, 4.84) 0.987
hsCRP, mg/L
< 0.9 (n=60) 1.00 1.00
0.9-3.3 (n=62) 1.90 (0.81, 4.46) 0.142 5.70 (1.00, 32.51) 0.050
>3.3 (n=61) 3.63 (1.59, 8.29) 0.002 8.00 (1.23, 51.94) 0.029
Not measured (n=17) 2.29 (0.84, 6.28) 0.107 0.94 (0.06, 15.95) 0.968
IL-6, pg/ml
< 0.3 (n=62) 1.00 1.00
0.3-1.9 (n=62) 1.89 (0.81, 4.41) 0.143 2.69 (0.54, 13.40) 0.227
>1.9 (n=64) 3.94 (1.74, 8.90) <.001 6.91 (1.21, 39.49) 0.030
Not measured (n=13) 2.69 (0.94, 7.67) 0.065 0.92 (0.06, 14.95) 0.954
P-selectin, ng/ml
< 157 (n=62) 1.00 1.00
157-236 (n=62) 0.95 (0.42, 2.13) 0.898 1.45 (0.29, 7.30) 0.649
>236 (n=64) 1.95 (0.91, 4.17) 0.085 6.20 (1.07, 35.89) 0.042
Not measured (n=13) 1.57 (0.58, 4.26) 0.378 0.66 (0.04, 10.09) 0.766
(b)
Biomarkers as continuous variables (Log Scale)
t-PA, ng/ml
per log2 higher 1.68 (1.09, 2.59) 0.019 1.15 (0.52, 2.56) 0.736
PAI-1, ng/ml
per log2 higher 1.12 (0.84, 1.48) 0.449 1.20 (0.71, 2.04) 0.498
D-dimer, ng/ml
per log2 higher 1.01 (0.79, 1.31) 0.911 0.89 (0.57, 1.38) 0.598
hsCRP, mg/l
per log2 higher 1.37 (1.14, 1.66) <.001 1.54 (1.03, 2.30) 0.036
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Table 3 Univariable and multivariable OR for CVD risk and biomarkers in early and late samples combined (Continued)
IL-6, pg/ml
per log2 higher 1.08 (0.90, 1.30) 0.408 1.22 (0.85, 1.74) 0.281
P-selectin, ng/ml
per log2 higher 1.70 (1.05, 2.75) 0.032 3.35 (1.20, 9.38) 0.022
Conditional Logistic Regression Model; CI = confidence interval; HDL = high-density lipoprotein; hsCRP = high-sensitivity C-reactive protein; IL-6 = interleukin-6;
IQR = interquartile range; NNRTI = nonnucleoside reverse transcriptase inhibitor; NRTI = nucleoside reverse transcriptase inhibitor; OR = odds ratio;
PAI-1 = plasminogen activator inhibitor-1; PI = protease inhibitor; t-PA = tissue plasminogen activator.
*Adjusted for calendar year, duration of time between the date of samples and the analysis time, age, total cholesterol, HDL, CD4+ cell count and viral load,
cumulative exposure to NRTI, NNRTI and PI prior to sample, and co-infection with hepatitis B or C.
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[34] The present study substantiates their results in the
Italian setting, using a standardized method for hsCRP
determination, and identifies 3.3 mg/L as a potential
threshold associated with an increased CVD risk in the
HIV-infected population. Moreover, we were able to
confirm the association between CRP and CVD risk
after controlling for eGFR, a factor potentially associ-
ated with both inflammation and CVD risk. However,
in disagreement with these findings, Ford et al. showed no
association between hsCRP and CVD events in treated
HIV-positive patients [2], while hsCRP was elevated in
individuals who were at low risk of a CVD event in the
study by Boger et al. [45].
Similar to hsCRP, IL-6 is a marker of inflammation
and has been associated with coronary heart disease
and endothelial dysfunction [46]: therefore its associ-
ation with cardiovascular events in this study is not
unexpected. An even stronger association between
IL-6 and myocardial infarction has been observed in
a previous large study [34]. Plasma P-selectin is
almost exclusively secreted by platelets and is associ-
ated with platelet activation, blood cell endothelial
adhesion and increased cardiovascular risk, in HIV
negative patients [47].
The limitations of the current study include the in-
ability to assess the risk of CVD associated with gen-
der (only 9 females were included) and the matching
variables (smoking status and diabetes). Also, we were
unable to control our estimates for potential differ-
ences in systolic blood pressure because a measure of
this parameter was available only in a minority of the
patients studied (not shown). Furthermore, time from
baseline was not one of the matching criteria as it is
generally the case in case–control studies nested
within a prospective cohort, although cases and con-
trols were matched within the same cohort. In
addition, controls have been, on average, exposed to
cART for longer than cases (by inclusion criteria,
controls had to have received cART for at least
5 years prior to the analysis time while there was nosuch restriction for cases), and, as a consequence,
biomarkers have been measured in more recent cal-
endar years. However, both factors were controlled
for in the multivariable analysis. Another limitation
relates to the different number of samples contrib-
uted by patients to the analysis, although there were
only minimal imbalances. Finally, the fact that no as-
sociation was found between t-PA, PAI-1 or D-dimer
and CVD risk in this study does not exclude their
role, as the study was not powered to detect such
associations.
The importance of evaluating, preventing and man-
aging CVD in patients with HIV is recognized in
guidelines for the use of antiretroviral agents in HIV-
infected adults [48]. Because hsCRP is cheap to meas-
ure and easily available it may become a clinically
useful tool to monitor CVD risk in HIV-positive
patients. Nevertheless, it has to be said that despite
the fact that hsCRP was found to be associated with
the risk of cardiovascular events independently of
traditional risk factors in the HIV-uninfected population,
the role of this biomarker in improving the prediction
of CVD of traditional risk scores remains controver-
sial even in the general population [49]. Moreover,
several caveats apply: substantial intra-individual vari-
ation in hsCRP levels may represent a problem
although, in the context of the general population,
the predictive value of single measures of this marker
was similar to that of repeated measures in the same
subjects; evidence showing that lowering hsCRP
reduces CVD events is available but not always con-
sistent, calling into question whether hsCRP is a relevant
therapeutic target; in addition, in a recent meta-analysis,
CRP was associated with a range of disorders, and not
just CVD [50].
In summary, our analysis shows that hsCRP is a
candidate biomarker predicting CVD risk in HIV-infected
patients receiving ART. Additional studies analyzing
the influence of the addition of this marker on the
prediction of cardiovascular risk scores are required
before implementation of routine measuring for the
scope of prediction into clinical practice.
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